Literature DB >> 15063895

Recurrent hepatocellular carcinoma after hepatic resection: prognostic factors and long-term outcome.

W-T Chen1, G-Y Chau, W-Y Lui, S-H Tsay, K-L King, C-C Loong, C-W Wu.   

Abstract

AIM: The prognosis of patients with recurrent hepatocellular carcinoma (HCC) after hepatic resection varies widely. This study analyzed long-term survival and prognostic factors of patients with recurrent HCC after hepatectomy.
METHODS: From July 1991 to December 2000, 623 patients underwent hepatic resection for HCC. Of those, 347 (56.5%) patients had tumour recurrence, and 286 patients with follow-up time more than 24 months after recurrence were enrolled. Twenty-seven clinicopathologic factors underwent both univariate and multivariate analysis.
RESULTS: Of these 286 patients, survival times after tumour recurrence were mean 672+/-619 days; median 468 days; and, range 10-3753 days. The overall 1-, 3-, 5-, and 10-year post-recurrence survival rates were 61.5, 33.4, 18.2, and 9.0%, respectively. Seventy (24.5%) patients were alive at the time of study, and 10 of the 34 patients who underwent re-resection were disease-free. By Cox regression analysis, multiple initial tumours (relative risk (RR) 1.428), recurrent multiple (RR 1.372), extrahepatic recurrence (RR 2.434), recurrent tumour size >2 cm (RR 1.926), post-hepatectomy period until recurrence <1 year (RR 1.769), and non-resectional treatment of recurrent tumours (RR 3.527) were independent prognostic factors for post-recurrent survival rates.
CONCLUSIONS: In patients with recurrent HCC after hepatectomy, both initial and recurrent tumour factors influenced their prognosis. Early detection of recurrent tumours is important. Re-resection correlated with better post-recurrent survival rates.

Entities:  

Mesh:

Year:  2004        PMID: 15063895     DOI: 10.1016/j.ejso.2004.01.013

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  33 in total

1.  Texture analysis of MR images to identify the differentiated degree in hepatocellular carcinoma: a retrospective study.

Authors:  Mengmeng Feng; Mengchao Zhang; Yuanqing Liu; Nan Jiang; Qian Meng; Jia Wang; Ziyun Yao; Wenjuan Gan; Hui Dai
Journal:  BMC Cancer       Date:  2020-06-30       Impact factor: 4.430

2.  Clinical analysis of the risk factors for recurrence of HCC and its relationship with HBV.

Authors:  Di-Peng Ou; Lian-Yue Yang; Geng-Wen Huang; Yi-Ming Tao; Xiang Ding; Zhi-Gang Chang
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

3.  Nomogram predicting long-term survival after the diagnosis of intrahepatic recurrence of hepatocellular carcinoma following an initial liver resection.

Authors:  Tsuyoshi Notake; Akira Kobayashi; Hiroji Shinkawa; Takuya Kawahara; Akira Shimizu; Takahide Yokoyama; Kiyoshi Hasegawa; Norihiro Kokudo; Yutaka Matsuyama; Masatoshi Makuuchi; Shin-Ichi Miyagawa
Journal:  Int J Clin Oncol       Date:  2017-03-16       Impact factor: 3.402

Review 4.  Resection of hepatitis B virus-related hepatocellular carcinoma: evolving strategies and emerging therapies to improve outcome.

Authors:  Gar-Yang Chau
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

Review 5.  The emerging role of positron emission tomography in hepatocellular carcinoma.

Authors:  Suraiya R Dubash; Oluwagbemiga A Idowu; Rohini Sharma
Journal:  Hepat Oncol       Date:  2015-04-27

6.  Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.

Authors:  Su Jong Yu; Chi Ma; Bernd Heinrich; Zachary J Brown; Milan Sandhu; Qianfei Zhang; Qiong Fu; David Agdashian; Umberto Rosato; Firouzeh Korangy; Tim F Greten
Journal:  J Hepatol       Date:  2018-11-09       Impact factor: 25.083

7.  Gender-based outcomes differences in unresectable hepatocellular carcinoma.

Authors:  Shama C Buch; Venkateswarlu Kondragunta; Robert A Branch; Brian I Carr
Journal:  Hepatol Int       Date:  2007-12-15       Impact factor: 6.047

8.  Adjuvant lipiodol I-131 after curative resection/ablation of hepatocellular carcinoma.

Authors:  K M Ng; R Niu; T D Yan; J Zhao; E McKay; F C K Chu; D L Morris
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

9.  Clinicopathological features of recurrence in patients after 10-year disease-free survival following curative hepatic resection of hepatocellular carcinoma.

Authors:  Masaki Kaibori; Shoji Kubo; Hiroaki Nagano; Michihiro Hayashi; Seiji Haji; Takuya Nakai; Morihiko Ishizaki; Kosuke Matsui; Takahiro Uenishi; Shigekazu Takemura; Hiroshi Wada; Shigeru Marubashi; Koji Komeda; Fumitoshi Hirokawa; Yasuyuki Nakata; Kazuhisa Uchiyama; A-Hon Kwon
Journal:  World J Surg       Date:  2013-04       Impact factor: 3.352

10.  Surgical treatment of hepatocellular carcinoma.

Authors:  Jacques Belghiti; Reza Kianmanesh
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.